Thomas Ried
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Ried has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Evelin Schröck
National Human Genome Research Institute/NIH
10 shared publications Evelin Schröck
National Human Genome Research Institute, National Institutes of Health , Building 49, Room 4A28, 49 Convent Drive, Bethesda, MD 20892-4470, USA
4 shared publicationsG Auer
3 shared publicationsH Blegen
3 shared publicationsY Ning
3 shared publicationsA C Hellström
2 shared publications
Latest Publications
- 16 August 2016
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 54 (08) , KV410
Der prognostische Wert des Ploidiestatus beim Mammakarzinom
Einleitung: Genomische Instabilität ist bei soliden Tumoren häufig mit einer schlechten Prognose assoziiert. Als ein mögliches Maß für die genomische Instabilität kann der Ploidiestatus herangezogen werden. Im Falle des Mammakarzinoms deuten bereits verschiedene Studien auf einen Zusammenhang zwischen dem Ploidiestatus von Tumorzellpopulationen und dem Überleben der Patientinnen hin. Ziele: Unsere Studie untersuchte in einem Kollektiv von Mammakarzinomfällen potentielle Zusammenhänge zwischen dem Ploidiestatus der Tumoren und dem Überleben der Patientinnen. Darüber hinaus wurden verschiedene klinische Parameter auf eine Assoziation mit dem Ploidiestatus eruiert. Methodik: Aus einer Kohorte von 5.580 Brustkrebs-Patientinnen wurden für die statistischen Analysen 100 Fälle, die eine spätere Metastasierung zeigten und weitere 100 nach Alter und Tumorstatus gematchte Fälle ohne Metastasierung, ausgewählt. Der Ploidiestatus der Tumoren wurde per Bildzytometrie bestimmt und in di-, tetra- und aneuploid kategorisiert. Deskriptive Statistik und Überlebensanalysen mittels Kaplan-Meier-Verfahren und Cox-Regression zeigten anschließend Zusammenhänge zwischen dem Ploidiestatus und klinischen Parametern wie der Überlebenszeit, Rezidiv-/Metastasenbildung oder dem Hormonrezeptorstatus. Ergebnis: Aneuploide Tumoren waren mit einem signifikant kürzeren Überleben assoziiert als di- oder tetraploide Tumoren (p = 0,01; HR = 1,2; 95% CI =[1,03;1,35]). Von den klinischen Parametern zeigte nur der Hormonrezeptorstatus einen Zusammenhang mit dem Ploidiestatus (p = 0,01). In separaten Überlebensanalysen für Hormonrezeptor-positive und -negative Fälle behielt der Ploidiestatus seinen prognostischen Wert in der Gruppe der Hormonrezeptor-positiven Fälle: Wie in der Gesamtkohorte waren die aneuploiden Tumoren mit einer signifikant schlechteren Prognose assoziiert (p = 0,02; HR = 1,2; 95% CI =[1,03;1,45]). Schlussfolgerung: Unsere Ergebnisse unterstützen die Rolle des Ploidiestatus als prognostischer Biomarker beim Mammakarzinom. Unter den Hormonrezeptor-positiven Brustkrebspatientinnen detektiert der Ploidiestatus eine Subgruppe mit einer signifikant schlechteren Prognose. Dies kann unter anderem bei der Entscheidung für eine zusätzliche adjuvante Chemotherapie neben der endokrinen Behandlung helfen.
- 16 August 2016
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 54 (08) , KV410
Der prognostische Wert des Ploidiestatus beim Mammakarzinom
Einleitung: Genomische Instabilität ist bei soliden Tumoren häufig mit einer schlechten Prognose assoziiert. Als ein mögliches Maß für die genomische Instabilität kann der Ploidiestatus herangezogen werden. Im Falle des Mammakarzinoms deuten bereits verschiedene Studien auf einen Zusammenhang zwischen dem Ploidiestatus von Tumorzellpopulationen und dem Überleben der Patientinnen hin. Ziele: Unsere Studie untersuchte in einem Kollektiv von Mammakarzinomfällen potentielle Zusammenhänge zwischen dem Ploidiestatus der Tumoren und dem Überleben der Patientinnen. Darüber hinaus wurden verschiedene klinische Parameter auf eine Assoziation mit dem Ploidiestatus eruiert. Methodik: Aus einer Kohorte von 5.580 Brustkrebs-Patientinnen wurden für die statistischen Analysen 100 Fälle, die eine spätere Metastasierung zeigten und weitere 100 nach Alter und Tumorstatus gematchte Fälle ohne Metastasierung, ausgewählt. Der Ploidiestatus der Tumoren wurde per Bildzytometrie bestimmt und in di-, tetra- und aneuploid kategorisiert. Deskriptive Statistik und Überlebensanalysen mittels Kaplan-Meier-Verfahren und Cox-Regression zeigten anschließend Zusammenhänge zwischen dem Ploidiestatus und klinischen Parametern wie der Überlebenszeit, Rezidiv-/Metastasenbildung oder dem Hormonrezeptorstatus. Ergebnis: Aneuploide Tumoren waren mit einem signifikant kürzeren Überleben assoziiert als di- oder tetraploide Tumoren (p = 0,01; HR = 1,2; 95% CI =[1,03;1,35]). Von den klinischen Parametern zeigte nur der Hormonrezeptorstatus einen Zusammenhang mit dem Ploidiestatus (p = 0,01). In separaten Überlebensanalysen für Hormonrezeptor-positive und -negative Fälle behielt der Ploidiestatus seinen prognostischen Wert in der Gruppe der Hormonrezeptor-positiven Fälle: Wie in der Gesamtkohorte waren die aneuploiden Tumoren mit einer signifikant schlechteren Prognose assoziiert (p = 0,02; HR = 1,2; 95% CI =[1,03;1,45]). Schlussfolgerung: Unsere Ergebnisse unterstützen die Rolle des Ploidiestatus als prognostischer Biomarker beim Mammakarzinom. Unter den Hormonrezeptor-positiven Brustkrebspatientinnen detektiert der Ploidiestatus eine Subgruppe mit einer signifikant schlechteren Prognose. Dies kann unter anderem bei der Entscheidung für eine zusätzliche adjuvante Chemotherapie neben der endokrinen Behandlung helfen.
- 15 November 2001
- Vol. 61 (22) , 8143-9
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis.
Here we report the genetic characterization of immortalized prostate epithelial cells before and after conversion to tumorigenicity using molecular cytogenetics and microarray technology. We were particularly interested to analyze the consequences of acquired chromosomal aneuploidies with respect to modifications of gene expression profiles. Compared with nontumorigenic but immortalized prostate epithelium, prostate tumor cell lines showed high levels of chromosomal rearrangements that led to gains of 1p, 5, 11q, 12p, 16q, and 20q and losses of 1pter, 11p, 17, 20p, 21, 22, and Y. Of 5700 unique targets on a 6.5K cDNA microarray, approximately 3% were subject to modification in expression levels; these included GRO-1, -2, IAP-1,- 2, MMP-9, and cyclin D1, which showed increased expression, and TRAIL, BRCA1, and CTNNA, which showed decreased expression. Thirty % of expression changes occurred in regions the genomic copy number of which remained balanced. Of the remainder, 42% of down-regulated and 51% of up-regulated genes mapped to regions present in decreased or increased genomic copy numbers, respectively. A relative gain or loss of a chromosome or chromosomal arm usually resulted in a statistically significant increase or decrease, respectively, in the average expression level of all of the genes on the chromosome. However, of these genes, very few (e.g., 5 of 101 genes on chromosome 11q), and in some instances only two genes (MMP-9 and PROCR on chromosome 20q), were overexpressed by > or =1.7-fold when scored individually. Cluster analysis by gene function suggests that prostate tumorigenesis in these cell line models involves alterations in gene expression that may favor invasion, prevent apoptosis, and promote growth.
- 15 November 2001
- Vol. 61 (22) , 8143-9
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis.
Here we report the genetic characterization of immortalized prostate epithelial cells before and after conversion to tumorigenicity using molecular cytogenetics and microarray technology. We were particularly interested to analyze the consequences of acquired chromosomal aneuploidies with respect to modifications of gene expression profiles. Compared with nontumorigenic but immortalized prostate epithelium, prostate tumor cell lines showed high levels of chromosomal rearrangements that led to gains of 1p, 5, 11q, 12p, 16q, and 20q and losses of 1pter, 11p, 17, 20p, 21, 22, and Y. Of 5700 unique targets on a 6.5K cDNA microarray, approximately 3% were subject to modification in expression levels; these included GRO-1, -2, IAP-1,- 2, MMP-9, and cyclin D1, which showed increased expression, and TRAIL, BRCA1, and CTNNA, which showed decreased expression. Thirty % of expression changes occurred in regions the genomic copy number of which remained balanced. Of the remainder, 42% of down-regulated and 51% of up-regulated genes mapped to regions present in decreased or increased genomic copy numbers, respectively. A relative gain or loss of a chromosome or chromosomal arm usually resulted in a statistically significant increase or decrease, respectively, in the average expression level of all of the genes on the chromosome. However, of these genes, very few (e.g., 5 of 101 genes on chromosome 11q), and in some instances only two genes (MMP-9 and PROCR on chromosome 20q), were overexpressed by > or =1.7-fold when scored individually. Cluster analysis by gene function suggests that prostate tumorigenesis in these cell line models involves alterations in gene expression that may favor invasion, prevent apoptosis, and promote growth.
- 1 May 1999
- Vol. 19 (5) , 480-2
Prenatal diagnosis of a mosaic extra structurally abnormal chromosome by spectral karyotyping.
A de novo mosaic extra structurally abnormal chromosome (ESAC) was detected in 33 per cent of cultured amniotic fluid cells from a pregnant woman. Neither Q-banding nor fluorescence in situ hybridization (FISH) employing a DNA probe for nucleolar organizer region demonstrated the presence of satellites on the ESAC. Spectral karyotyping (SKY) was performed in this prenatal case and led to a quick and accurate determination of the ESAC as chromosome 14 in origin. The SKY finding was confirmed by conventional FISH analysis using a chromosome 14 specific painting probe. Subsequent hybridizations with a centromeric probe and a 14q subtelomeric probe were also performed to further characterize the ESAC. Absence of (TTAGGG)n sequence on the ESAC, determined postnatally, suggested it is a ring chromosome 14. Genetic counselling concerning these findings was provided to the parents who chose to continue the pregnancy. The male infant had no apparent abnormal phenotype at birth.
- 1 May 1999
- Vol. 19 (5) , 480-2
Prenatal diagnosis of a mosaic extra structurally abnormal chromosome by spectral karyotyping.
A de novo mosaic extra structurally abnormal chromosome (ESAC) was detected in 33 per cent of cultured amniotic fluid cells from a pregnant woman. Neither Q-banding nor fluorescence in situ hybridization (FISH) employing a DNA probe for nucleolar organizer region demonstrated the presence of satellites on the ESAC. Spectral karyotyping (SKY) was performed in this prenatal case and led to a quick and accurate determination of the ESAC as chromosome 14 in origin. The SKY finding was confirmed by conventional FISH analysis using a chromosome 14 specific painting probe. Subsequent hybridizations with a centromeric probe and a 14q subtelomeric probe were also performed to further characterize the ESAC. Absence of (TTAGGG)n sequence on the ESAC, determined postnatally, suggested it is a ring chromosome 14. Genetic counselling concerning these findings was provided to the parents who chose to continue the pregnancy. The male infant had no apparent abnormal phenotype at birth.
- 1 January 1999
- Vol. 10 (2) , 195-6
A mosaic extra ring chromosome 4 in a female patient with postnatal overgrowth.
- 1 January 1999
- Vol. 10 (2) , 195-6
A mosaic extra ring chromosome 4 in a female patient with postnatal overgrowth.
- 4 December 1998
- Vol. 80 (4) , 368-72
Identification of an unusual marker chromosome by spectral karyotyping.
We ascertained a newborn girl with multiple congenital anomalies including severe hypotonia, cardiovascular defects, hearing loss, central nervous system anomalies, and facial anomalies. The infant died at 12 days. Cytogenetic analysis showed a de novo supernumerary marker chromosome. Fluorescence in situ hybridization (FISH) with a combination of chromosome specific alpha-satellite probes and an all-human centromere probe failed to show hybridization to the marker, indicating that the marker chromosome lacked detectable alpha satellite sequences. Spectral karyotyping (SKY) was performed and showed that the marker was chromosome 15 in origin. This was confirmed by FISH with a 15q specific subtelomerie probe, which showed hybridization to both ends of the marker chromosome. Based on FISH information and G-banding pattern, the marker was determined to be an inverted duplication of 15q25-qter, leading to partial tetrasomy for chromosome 15. Although the marker chromosome lacked detectable centromeric alpha-satellite sequences, it seemed to have a functional centromere as it is mitotically stable. This observation is consistent with previous studies on acentric marker chromosomes, which suggested that the DNA sequence at the breakpoint could function similarly to alpha-satellite sequences once activated through marker formation.
- 4 December 1998
- Vol. 80 (4) , 368-72
Identification of an unusual marker chromosome by spectral karyotyping.
We ascertained a newborn girl with multiple congenital anomalies including severe hypotonia, cardiovascular defects, hearing loss, central nervous system anomalies, and facial anomalies. The infant died at 12 days. Cytogenetic analysis showed a de novo supernumerary marker chromosome. Fluorescence in situ hybridization (FISH) with a combination of chromosome specific alpha-satellite probes and an all-human centromere probe failed to show hybridization to the marker, indicating that the marker chromosome lacked detectable alpha satellite sequences. Spectral karyotyping (SKY) was performed and showed that the marker was chromosome 15 in origin. This was confirmed by FISH with a 15q specific subtelomerie probe, which showed hybridization to both ends of the marker chromosome. Based on FISH information and G-banding pattern, the marker was determined to be an inverted duplication of 15q25-qter, leading to partial tetrasomy for chromosome 15. Although the marker chromosome lacked detectable centromeric alpha-satellite sequences, it seemed to have a functional centromere as it is mitotically stable. This observation is consistent with previous studies on acentric marker chromosomes, which suggested that the DNA sequence at the breakpoint could function similarly to alpha-satellite sequences once activated through marker formation.
- 1 November 1998
- Vol. 18 (11) , 1174-80
FISH analysis of a complex chromosome rearrangement involving nine breakpoints on chromosomes 6, 12, 14 and 16.
We report the prenatal diagnosis of an apparently balanced de novo complex chromosome rearrangement (CCR) which involved nine breakpoints on four different chromosomes. Fluorescence in situ hybridization (FISH) and spectral karyotyping (SKY) were performed as an adjunct to G-banding for characterization of the abnormal chromosomes. The 22-week female fetus showed minor dysmorphic features including dolichocephaly, broad fingernails, tibial bowing, clubfoot, thoracolumbar scoliosis and hypoplastic toenails. Autopsy revealed gall-bladder hypoplasia and an atrial septal defect. Chromosome analysis of fetal tissue confirmed the presence of the complex rearrangement.
- 1 November 1998
- Vol. 18 (11) , 1174-80
FISH analysis of a complex chromosome rearrangement involving nine breakpoints on chromosomes 6, 12, 14 and 16.
We report the prenatal diagnosis of an apparently balanced de novo complex chromosome rearrangement (CCR) which involved nine breakpoints on four different chromosomes. Fluorescence in situ hybridization (FISH) and spectral karyotyping (SKY) were performed as an adjunct to G-banding for characterization of the abnormal chromosomes. The 22-week female fetus showed minor dysmorphic features including dolichocephaly, broad fingernails, tibial bowing, clubfoot, thoracolumbar scoliosis and hypoplastic toenails. Autopsy revealed gall-bladder hypoplasia and an atrial septal defect. Chromosome analysis of fetal tissue confirmed the presence of the complex rearrangement.
- 1 September 1998
- Vol. 92 (5) , 1743-8
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma.
Karyotypic information on multiple myeloma (MM) is less extensive than that on other myeloid or lymphoid malignancies due to low mitotic activity of plasma cells. An add(14)(q32) marker chromosome has been reported to be the most frequent recurring abnormality in clonally abnormal cases; in approximately one third of the latter cases, this marker has been identified as a der(14)t(11;14)(q13;q32) chromosome. To map chromosomal breakpoints, characterize the add(14)(q32) marker chromosomes, and to identify other recurring translocations in MM, we used spectral karyotyping (SKY) to analyze a panel of nine bone marrow (BM) biopsy samples from eight patients and 10 tumor cell lines derived from MM patients. SKY involves hybridization of 24 fluorescently labeled chromosome painting probes to metaphase spreads in such a manner that simultaneous visualization of each of the chromosomes in a different color is accomplished. By this method, it was possible to define all chromosomal rearrangements and identify all of the clonal marker chromosomes in tumor cells. By detailed mapping of breakpoints of rearrangement, it was also possible to identify several novel recurring sites of breakage that map to the chromosomal bands 3q27, 17q24-25, and 20q11. The partner chromosomes in translocations that generated the add (14)(q32) marker chromosomes were identified in all cases in which they were detected by G-banding (one biopsy and six cell lines). In addition, two new translocations involving band 14q32, ie, t(12;14)(q24;q32) and t(14;20)(q32;q11) have also been identified. These studies demonstrate the power of SKY in resolving the full spectrum of chromosome abnormalities in tumors.
- 1 September 1998
- Vol. 92 (5) , 1743-8
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma.
Karyotypic information on multiple myeloma (MM) is less extensive than that on other myeloid or lymphoid malignancies due to low mitotic activity of plasma cells. An add(14)(q32) marker chromosome has been reported to be the most frequent recurring abnormality in clonally abnormal cases; in approximately one third of the latter cases, this marker has been identified as a der(14)t(11;14)(q13;q32) chromosome. To map chromosomal breakpoints, characterize the add(14)(q32) marker chromosomes, and to identify other recurring translocations in MM, we used spectral karyotyping (SKY) to analyze a panel of nine bone marrow (BM) biopsy samples from eight patients and 10 tumor cell lines derived from MM patients. SKY involves hybridization of 24 fluorescently labeled chromosome painting probes to metaphase spreads in such a manner that simultaneous visualization of each of the chromosomes in a different color is accomplished. By this method, it was possible to define all chromosomal rearrangements and identify all of the clonal marker chromosomes in tumor cells. By detailed mapping of breakpoints of rearrangement, it was also possible to identify several novel recurring sites of breakage that map to the chromosomal bands 3q27, 17q24-25, and 20q11. The partner chromosomes in translocations that generated the add (14)(q32) marker chromosomes were identified in all cases in which they were detected by G-banding (one biopsy and six cell lines). In addition, two new translocations involving band 14q32, ie, t(12;14)(q24;q32) and t(14;20)(q32;q11) have also been identified. These studies demonstrate the power of SKY in resolving the full spectrum of chromosome abnormalities in tumors.
- Open Access
- 1 September 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (10) , 1619-1626
Chromosome painting: a useful art
Chromosome ‘painting’ refers to the hybridization of fluorescently labeled chromosome-specific, composite probe pools to cytological preparations. Chromosome painting allows the visualization of individual chromosomes in metaphase or interphase cells and the identification of both numerical and structural chromosomal aberrations in human pathology with high sensitivity and specificity. In addition to human chromosome-specific probe pools, painting probes have become available for an increasing range of different species. They can be applied to cross-species comparisons as well as to the study of chromosomal rearrangements in animal models of human diseases. The simultaneous hybridization of multiple chromosome painting probes, each tagged with a specific fluorochrome or fluorochrome combination, has resulted in the differential color display of human (and mouse) chromosomes, i.e. color karyotyping. In this review, we will summarize recent developments of multicolor chromosome painting, describe applications in basic chromosome research and cytogenetic diagnostics, and discuss limitations and future directions.
- 1 September 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (10) , 1619-1626
Open AccessChromosome painting: a useful art
Chromosome ‘painting’ refers to the hybridization of fluorescently labeled chromosome-specific, composite probe pools to cytological preparations. Chromosome painting allows the visualization of individual chromosomes in metaphase or interphase cells and the identification of both numerical and structural chromosomal aberrations in human pathology with high sensitivity and specificity. In addition to human chromosome-specific probe pools, painting probes have become available for an increasing range of different species. They can be applied to cross-species comparisons as well as to the study of chromosomal rearrangements in animal models of human diseases. The simultaneous hybridization of multiple chromosome painting probes, each tagged with a specific fluorochrome or fluorochrome combination, has resulted in the differential color display of human (and mouse) chromosomes, i.e. color karyotyping. In this review, we will summarize recent developments of multicolor chromosome painting, describe applications in basic chromosome research and cytogenetic diagnostics, and discuss limitations and future directions.
- 1 July 1998
- Vol. 17 (3) , 245-54
Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations.
Primary fallopian tube carcinoma (PFTC) is a rare and highly aggressive tumor. Twelve cases of PFTC (stages IA to IV) were analyzed by comparative genomic hybridization. The most consistent DNA gain was mapped to chromosome arm 3q in 11 of 12 cases. In six cases, the gain of 3q was present as a high level copy number increase (amplification) with a consensus region mapped to 3q26.2-qter. In the 12 cases, other frequent gains were located on chromosome arms 1q (in 11 cases), 2q (in 10), 7q (in 9), 8q (in 9), 5p (in 8), 6p (in 7), 12p (in 7), and 14q (in 6). Frequent copy number losses occurred on chromosome arms 16q (in 8 cases), 22q (in7), 6q (in 6). 8p (in 6), 18q (in 6), Xq (in 6), 1p (in 5), and 17p (in 5). All chromosomes were involved in chromosomal aberrations and the average number of copy alterations per case was 19.7. None of the 12 carcinomas revealed the presence of human papillomavirus (HPV) genomes. All of the cases exhibited crude aneuploidy. Strong p53 immunoreactivity could be observed in 10 of 12 cases while p21/WAF1 expression was low or undetectable. These results indicate that PFTC is a genomically highly unstable cancer, an observation that is in agreement with the poor prognosis associated with this tumor. A high frequency of 3q-gains has also been observed in HPV-related carcinomas of the uterine cervix. However, none of the PFTC was HPV related, suggesting that the 3q-gain is independent from HPV DNA.
- 1 July 1998
- Vol. 17 (3) , 245-54
Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations.
Primary fallopian tube carcinoma (PFTC) is a rare and highly aggressive tumor. Twelve cases of PFTC (stages IA to IV) were analyzed by comparative genomic hybridization. The most consistent DNA gain was mapped to chromosome arm 3q in 11 of 12 cases. In six cases, the gain of 3q was present as a high level copy number increase (amplification) with a consensus region mapped to 3q26.2-qter. In the 12 cases, other frequent gains were located on chromosome arms 1q (in 11 cases), 2q (in 10), 7q (in 9), 8q (in 9), 5p (in 8), 6p (in 7), 12p (in 7), and 14q (in 6). Frequent copy number losses occurred on chromosome arms 16q (in 8 cases), 22q (in7), 6q (in 6). 8p (in 6), 18q (in 6), Xq (in 6), 1p (in 5), and 17p (in 5). All chromosomes were involved in chromosomal aberrations and the average number of copy alterations per case was 19.7. None of the 12 carcinomas revealed the presence of human papillomavirus (HPV) genomes. All of the cases exhibited crude aneuploidy. Strong p53 immunoreactivity could be observed in 10 of 12 cases while p21/WAF1 expression was low or undetectable. These results indicate that PFTC is a genomically highly unstable cancer, an observation that is in agreement with the poor prognosis associated with this tumor. A high frequency of 3q-gains has also been observed in HPV-related carcinomas of the uterine cervix. However, none of the PFTC was HPV related, suggesting that the 3q-gain is independent from HPV DNA.
- 15 June 1998
- Vol. 91 (12) , 4457-63
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Dysregulation of oncogenes by translocation to an IgH (14q32) or IgL (kappa, 2p11 or lambda, 22q11) locus is a frequent event in the pathogenesis of B-cell tumors. Translocations involving an IgH locus and a diverse but nonrandom array of chromosomal loci occur in most multiple myeloma (MM) tumors even though the translocations often are not detected by conventional cytogenetic analysis. In a continuing analysis of translocations in 21 MM lines, we show that the novel, karyotypically silent t(14;16)(q32.3;q23) translocation is present in 5 MM lines, with cloned breakpoints from 4 lines dispersed over an approximately 500-kb region centromeric to the c-maf proto-oncogene at 16q23. Another line has a t(16;22)(q23;q11), with the breakpoint telomeric to c-maf, so that the translocation breakpoints in these 6 lines bracket c-maf. Only these 6 lines overexpress c-maf mRNA. As predicted for dysregulation of c-maf by translocation, there is selective expression of one c-maf allele in 2 informative lines with translocations. This is the first human tumor in which the basic zipper c-maf transcription factor is shown to function as an oncogene.
- 15 June 1998
- Vol. 91 (12) , 4457-63
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Dysregulation of oncogenes by translocation to an IgH (14q32) or IgL (kappa, 2p11 or lambda, 22q11) locus is a frequent event in the pathogenesis of B-cell tumors. Translocations involving an IgH locus and a diverse but nonrandom array of chromosomal loci occur in most multiple myeloma (MM) tumors even though the translocations often are not detected by conventional cytogenetic analysis. In a continuing analysis of translocations in 21 MM lines, we show that the novel, karyotypically silent t(14;16)(q32.3;q23) translocation is present in 5 MM lines, with cloned breakpoints from 4 lines dispersed over an approximately 500-kb region centromeric to the c-maf proto-oncogene at 16q23. Another line has a t(16;22)(q23;q11), with the breakpoint telomeric to c-maf, so that the translocation breakpoints in these 6 lines bracket c-maf. Only these 6 lines overexpress c-maf mRNA. As predicted for dysregulation of c-maf by translocation, there is selective expression of one c-maf allele in 2 informative lines with translocations. This is the first human tumor in which the basic zipper c-maf transcription factor is shown to function as an oncogene.